Scholarlink

Background <p>Fungal periprosthetic joint infection remains a challenging complication in revision arthroplasty. <i>Candida albicans</i> (<i>C. albicans</i>) is among the most frequently reported fungal pathogens, and biofilm formation further limits antifungal efficacy. Tranexamic acid (TXA) is routinely used to reduce perioperative blood loss in arthroplasty and may come into direct contact with antifungal agents within the joint environment. However, whether TXA modifies antifungal activity against <i>C. albicans</i> remains unclear. This study aimed to evaluate the effect of TXA on the in vitro activity of representative antifungal agents against <i>C. albicans</i> under planktonic and established biofilm conditions.</p> Results <p>Baseline planktonic MICs for FLC, VRC, CAS, and AMB were 0.75, 0.5, 1, and 0.75&#xa0;µg/mL, respectively. In the presence of TXA, susceptibility shifts were class-dependent: MICs for VRC and CAS decreased four-fold and two-fold, respectively, while AMB exhibited a two-fold increase and FLC remained unchanged. Established biofilms showed markedly reduced antifungal susceptibility, and TXA further altered the XTT-derived biofilm metabolic inhibition profiles. For FLC, TXA increased peak metabolic inhibition from approximately 50–55% in saline to 85–90%, with an XTT-derived MBEC₉₀ of 192&#xa0;µg/mL. In contrast, TXA attenuated VRC-mediated biofilm metabolic inhibition, producing a right-shifted dose-response profile relative to saline conditions. For CAS, TXA lowered the XTT-derived activity threshold from 256 to 128&#xa0;µg/mL, although the response curves converged at higher concentrations. For AMB, TXA reduced apparent biofilm activity, increasing the XTT-derived minimum biofilm eradication concentrations (MBECs) threshold from 1.5 to 12&#xa0;µg/mL.</p> Conclusions <p>TXA differentially modulated the apparent in vitro activity of representative antifungal agents against <i>C. albicans</i> in an antifungal class- and growth-state-dependent manner. The discordance between planktonic and antibiofilm responses under TXA co-exposure supports further mechanistic and translational validation in clinically relevant <i>Candida</i> biofilm models.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of tranexamic acid on planktonic and biofilm susceptibility of Candida albicans

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月30日

查看全文
  • Liqin Yao,
  • Rui Liu,
  • Qiangde Hu,
  • Yicheng Li,
  • Boyong Xu,
  • Xiaogang Zhang,
  • Li Cao,
  • Wenbo Mu

摘要

Background

Fungal periprosthetic joint infection remains a challenging complication in revision arthroplasty. Candida albicans (C. albicans) is among the most frequently reported fungal pathogens, and biofilm formation further limits antifungal efficacy. Tranexamic acid (TXA) is routinely used to reduce perioperative blood loss in arthroplasty and may come into direct contact with antifungal agents within the joint environment. However, whether TXA modifies antifungal activity against C. albicans remains unclear. This study aimed to evaluate the effect of TXA on the in vitro activity of representative antifungal agents against C. albicans under planktonic and established biofilm conditions.

Results

Baseline planktonic MICs for FLC, VRC, CAS, and AMB were 0.75, 0.5, 1, and 0.75 µg/mL, respectively. In the presence of TXA, susceptibility shifts were class-dependent: MICs for VRC and CAS decreased four-fold and two-fold, respectively, while AMB exhibited a two-fold increase and FLC remained unchanged. Established biofilms showed markedly reduced antifungal susceptibility, and TXA further altered the XTT-derived biofilm metabolic inhibition profiles. For FLC, TXA increased peak metabolic inhibition from approximately 50–55% in saline to 85–90%, with an XTT-derived MBEC₉₀ of 192 µg/mL. In contrast, TXA attenuated VRC-mediated biofilm metabolic inhibition, producing a right-shifted dose-response profile relative to saline conditions. For CAS, TXA lowered the XTT-derived activity threshold from 256 to 128 µg/mL, although the response curves converged at higher concentrations. For AMB, TXA reduced apparent biofilm activity, increasing the XTT-derived minimum biofilm eradication concentrations (MBECs) threshold from 1.5 to 12 µg/mL.

Conclusions

TXA differentially modulated the apparent in vitro activity of representative antifungal agents against C. albicans in an antifungal class- and growth-state-dependent manner. The discordance between planktonic and antibiofilm responses under TXA co-exposure supports further mechanistic and translational validation in clinically relevant Candida biofilm models.